Would you move to a venetoclax-based regimen for a patient with pentarefractory MM and t(11;14) translocation, previously treated with bortezomib and carfilzomib?

To clarify what is meant by pentarefractory, we are referring to a situation where a patient's myeloma has proven resistant to two proteasome inhibitors (bortezomib, carfilzomib), two IMiDs (lenalidomide/pomalidomide), and an anti-CD38 monoclonal antibody (daratumumab/isatuximab). There are not many...

I like the important point about verifying that t(11;14) is the bulk of the patient's relapsed myeloma acknowledging a patchy & potentially diverse marrow. I also appreciate caution regarding CYP3A4 interactions, although anti fungal prophylaxis is not common in myeloma. Finally, I agree with Veneto...